Insight Molecular (NASDAQ: IMDX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.24) by 29.17 percent. This is a 3.33 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $239.000 thousand which missed the analyst consensus estimate of $437.500 thousand by 45.37 percent. This is a 53.86 percent decrease over sales of $518.000 thousand the same period last year.